Introduction Severe hypoglycaemia (SH), when blood glucose falls too low to support brain function, is the most feared acute complication of insulin therapy for type 1 diabetes mellitus (T1DM). 10% of people with T1DM contribute nearly 70% of all episodes, with impaired awareness of hypoglycaemia (IAH) a major risk factor. People with IAH may be refractory to conventional approaches to reduce SH, with evidence for cognitive barriers to hypoglycaemia avoidance. This paper describes the protocol for the Hypoglycaemia Awareness Restoration Programme for People with Type 1 Diabetes and Problematic Hypoglycaemia Persisting Despite Optimised Self-care (HARPdoc) study, a trial to assess the impact on hypoglycaemia experience of a novel intervention that addresses cognitive barriers to hypoglycaemia avoidance, compared with an existing control intervention, recommended by the National Institute of Health and Care Excellence.
Methods and analysis A randomised parallel two-arm trial of two group therapies: HARPdoc versus Blood Glucose Awareness Training, among 96 adults with T1DM and problematic hypoglycaemia, despite attendance at education with or without technology use, in four centres providing specialist T1DM services. The primary outcome will be the SH rate at 12 and/or 24 months after randomisation to either course. Secondary outcomes include rates of SH requiring parenteral therapy, involving unconsciousness or needing emergency services; hypoglycaemia awareness status, overall diabetes control and quality of life measures. An implementation study to evaluate how the interventions are delivered and how implementation impacts on clinical effectiveness is planned as a parallel study, with its own protocol.
Ethics and dissemination The protocol was approved by the London Dulwich Research Ethics Committee, the Health Research Authority, National Health Service R&D and the Institutional Review Board of the Joslin Diabetes Center in the USA. Study findings will be disseminated to study participants and through peer-reviewed publications and conference presentations, including user groups.
Trial registration number NCY02940873; Pre-results.
- general diabetes
- cognitive theory
- randomised controlled trial
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Strengths and limitations of this study
A randomised trial of two active interventions, one novel and one established, for a very vulnerable group of people, failing to achieve safety using conventional management strategies, which themselves have been subject to a systematic review.
The trial targets severe hypoglycaemia in adults with type 1 diabetes, a major challenge for people with the condition, their families and the healthcare systems supporting them.
The novel intervention addresses cognitions, identified as barriers to behaviour change, in the maintenance of behaviours that create high risk of continuing to experience severe hypoglycaemia, while the comparator intervention has not previously been tested in the National Health Service.
The study is run in four specialist diabetes services, in the UK and the USA, and is supported in its delivery by a certified clinical trial unit.
The study requires correct identification of people whose hypoglycaemia problem has remained refractory to conventional management.
Severe hypoglycaemia (SH) is the most feared acute complication of insulin therapy for insulin deficient (type 1 and late type 2) diabetes.1 SH occurs when plasma glucose concentrations fall so low that the person experiencing the hypoglycaemia is rendered incapable of self-treatment and/or experiences loss of consciousness or seizure.2 SH causes confusion, abnormal behaviour, family trauma, restricted work opportunities3 4 and sudden cardiac death.5 Each year, about 40% of people with type 1 diabetes mellitus (T1DM) will experience SH.6 Four to 10% of deaths in adults with T1DM under the age of 40 years may be due to SH,7–10 with 550–1391 deaths attributed to it annually in England and Wales.11 Fear of hypoglycaemia can prevent people with diabetes achieving the glucose control associated with reduced risk of long-term vascular complications of diabetes,1 which can affect the eyes, kidneys and peripheral nerves and drive premature cardiovascular and cerebrovascular disease.12
People with T1DM have defects in endogenous counter-regulatory mechanisms that maintain plasma glucose.13 14 Their best protection against SH is subjective awareness of the start of a plasma glucose fall, driving ingestion of rapidly absorbed carbohydrate. Impaired awareness of hypoglycaemia (IAH) is a major predictors of SH,6 increasing risk of SH sixfold to eightfold in T1DM.15 16. IAH affects 25%–40% of people with T1DM of 15+ years’ duration.15 16 IAH impairs quality of life, causing loss of privileges such as licence to drive and problems at home and at work.4 17 18
IAH is associated with defects in the subjective and counter-regulatory neuroendocrine responses to hypoglycaemia, additional to the inability to regulate insulin and glucagon concentrations in response to hypoglycaemia of T1DM.19 These defects are inducible by exposure to hypoglycaemia20 21 and reversible by avoidance of plasma glucose <3 mmol/L (<54 mg/dL).22–24 Hypoglycaemia awareness and/or reduced risk of SH can be restored in clinical settings. A meta-analysis of structured education in flexible insulin therapy, aiming to transfer skills of insulin dose adjustment to users, or to enhance people’s subjective ability to detect or predict extremes of plasma glucose and avoid them, showed significant reductions in SH,25 with additional evidence from the comparison of optimised MDI (multiple daily insulin injections) vs pumps with or without sensors in severe hypoglycaemia (HypoCOMPaSS) trial.26 Two programmes, the UK’s Dose Adjustment for Normal Eating (DAFNE) and the US programme Blood Glucose Awareness Training (BGAT)27–29 have also been shown to restore awareness of hypoglycaemia to some. Forty-three per cent of those entering DAFNE with IAH had recovered awareness at 1 year, patients then reporting IAH contributing almost all the residual SH in the programme.16 Newer technologies for insulin delivery (continuous subcutaneous insulin infusion, CSII) and continuous glucose monitoring (CGM) and sensor augmented pump therapy can also reduce SH.30–33 However, there are no data on the impact of CSII on IAH, and use of real-time CGM does not restore IAH, making patients dependent on the technology long-term.34 Guidelines suggest a stepwise approach through education and technology, but some people continue to report IAH and SH16; some cannot engage successfully with technological interventions.35 Anecdotally, people gaining protection from SH using CGM experience SH when not wearing the devices. As the last resort, beta-cell replacement by islet or pancreas transplantation is an option36 but is costly, requires long-term immunosuppression and is not universally available or acceptable. Additional interventions are urgently needed.
Some people with IAH show unexpectedly low concern about the consequences of their hypoglycaemia experience and describe beliefs about their hypoglycaemia that may be barriers to future hypoglycaemia avoidance.37 38 In a Swedish study, 8% of people were at high risk of SH but had low concern about it.39 In a UK clinic audit, people with IAH were less likely to use strategies decided on in clinic consultations than people with hypoglycaemia awareness.40
Based on the above evidence, we hypothesised that an intervention that directly addresses the described cognitive and motivational barriers to hypoglycaemia avoidance will help those with IAH and SH that has persisted after conventional structured education in flexible intensive insulin therapy to recover awareness and reduce SH experience. We therefore designed an intervention that uniquely includes a curriculum that addresses these cognitive and motivational barriers. The curriculum for the 6-week intervention was codesigned by researchers, diabetes specialists, diabetes educators, people with diabetes and psychologists led by clinical psychologist NDZ. It was devised to be delivered by two diabetes educators, supervised by a clinical psychologist. A second curriculum was constructed for training the educators. A pilot study showed the intervention reduced SH rates from well above to below the reported average over the following year.41 Patients, family members and educators were interviewed.42 43 Their comments were incorporated into a revised curriculum, the Hypoglycaemia Awareness Restoration Programme for People With Type 1 Diabetes and Problematic Hypoglycaemia Persisting Despite Optimised Self-care or HARPdoc. The trial reported here explores the clinical, cost and implementation effectiveness of HARPdoc.
Choice of comparator was complex, as the participants to be recruited into this trial will have been exposed to routinely available options, and they are a vulnerable patient group by virtue of their SH. BGAT, described below, was selected.27–29 The UK’s National Institute for Health and Clinical Excellence (NICE) recommended BGAT for T1DM adults with problematic hypoglycaemia,44 although BGAT is not currently offered in the UK and has not formally been tested in people who have already completed structured education in flexible intensive insulin therapy as offered there that should have minimised SH risk.45
The main trial objective is therefore to compare the impact of the two programmes on hypoglycaemia experience, particularly SH experience, at 1 and 2 years after participation.
Methods and analysis
This is a randomised parallel two-arm trial of group therapies with rate of SH expressed per year measured at 1 and 2 years postrandomisation as two primary endpoints, comparing the novel psychotherapeutically enhanced education intervention HARPdoc with the control intervention BGAT. The trial was started in March 2017, and the estimated primary completion date is July 2021.
The trial will be run in specialist care diabetes centres that support adults with T1DM: King’s Health Partners (comprising King’s College and Guy’s and St Thomas’ Hospitals NHS Foundation Trusts, London, UK); Sheffield Teaching Hospitals NHS Foundation Trust, UK; Royal Bournemouth Hospital, Bournemouth, UK, and the Joslin Diabetes Center, Boston, Massachusetts, USA. All provide structured education in flexible insulin therapy (DAFNE, BERTIE (Bournemouth Type 1 diabetes education) or the Joslin programme, DO-IT or Diabetes Outpatient Intensive Treatment), have clinical capability in use of CSII and CGM and routinely receive tertiary referrals for problematic hypoglycaemia.
Participants who have expressed interest in the study, have consented and have IAH but do not meet all the trial inclusion criteria may be included in courses as ‘Non-randomised participants’ to ensure there are at least four people in each group, which is essential for creating the group format, allowing for one drop out. The information sheet for these participants is available in online supplementary file 1.
Supplementary file 1:
Hypoglycaemia Awareness Restoration Programme for People with Type 1 Diabetes and Problematic Hypoglycaemia Persisting Despite Optimised Self-care
The curriculum incorporates re-education in the mechanisms, outcomes, treatment and prevention of hypoglycaemia and hypoglycaemia unawareness. The novelty lies in incorporating a motivational interviewing (MI) approach to elicit and strengthen commitment to change and cognitive behaviour theory (CBT) to identify and restructure unhelpful cognitions. Three ‘thinking traps’ (based on qualitative research with people with IAH37 41) will be introduced using cartoon metaphors and visual aids to make them more accessible. The first trap is the belief that one could ‘soldier on’ through hypoglycaemic episodes and delay treatment; the second that there were no important adverse outcomes to hypoglycaemia and/or IAH and the third overestimation of the risks of intermittent hyperglycaemia. Other psychological techniques used in regular education will be retained: social learning theory; a group structure; patient empowerment and an enabling, non-judgemental approach.
The curriculum will be delivered by two diabetes educators, to four to eight participants, over 6 weeks (table 2). In weeks 1–3, participants meet weekly in full-day sessions. They cover the pathophysiology, presentation, detection and treatment of hypoglycaemia and IAH and use MI to support behaviour change and encourage small changes, with CBT-informed strategies to address unhelpful cognitions. In weeks 4 and 5, participants will try out their new skills/strategies, with two individual support appointments (face to face or telephone). Week 6 is a final group session, focusing on relapse prevention and support for relatives who will be invited to participate, with their own session led by the psychologist. Group follow-up sessions (following an MI approach) will be scheduled at data collection times of 3, 6 and 12 months post-randomisation.
Scheduled supervision will be provided to HARPdoc educators by the study clinical psychologist, with debriefing sessions, weekly during the 6 week courses, and at 3, 6 and 12 month follow-ups, with further sessions available to support educators providing unscheduled one-to-one sessions to participants over the first year. In these, the educators will be able to describe the participants’ progress and gain feedback on how to manage issues that arise.
Blood Glucose Awareness Training
BGAT is a well-established manualised intervention that is suitable for group or one-to-one delivery with a single diabetes educator.27 It teaches participants to focus on new ways of predicting extremes of blood glucose, through paying greater attention to internal cues (feelings and experiences) and providing greater understanding of external cues—drivers of high and low blood glucose. BGAT reviews the pharmacodynamics of insulin and glucose absorption from meals with careful and systematised recording and reflection on participants’ own data. It is designed in eight classes, originally envisaged as each taken over 2 hours. In the present study, groups of participants will work through the BGAT manual text, led by one diabetes educator. For practical reasons (participants will be booked into courses before knowing which course they will receive), the BGAT curriculum will be delivered in four group sessions (two sessions in single-day attendances in weeks 1, 2, 3 and 6), with an optional telephone/Skype follow-up during weeks 4 or 5. The curriculum will not be extended to ensure that group sessions necessarily occupy the same hours as HARPdoc.
Training the educators
A 3-day workshop was held during the planning of the study, which included protocol discussion, intervention training and creating appropriate course documents for UK and US centres. HARPdoc educator training was consolidated over 6 weeks following initial training, through weekly emailed homework practice and review by the study psychologist of recorded simulated one-to-one sessions with a medical actor to support educators reach the required skills competency. Care has and will be taken to keep the two groups of educators separate, to avoid contamination, throughout the study.
Attendance of least the first three group sessions for either course plus, for HARPdoc, at least one 1:1 session will be considered participation in the intervention. In the case of involuntary non-attendance of one of the course sessions (eg, unexpected illness), the participants’ educator/s will review with the principal investigator (PI) whether a replacement ‘catch-up’ session is feasible. These will be documented as unscheduled contact, as will any contacts made to support course learning outside the main course delivery.
Patient and public involvement
Improvement in awareness and prevention of hypoglycaemia was identified explicitly as a research priority (number 6 of 10) by people with type 1 diabetes and their carers collaboratively with researchers and healthcare professionals in a James Lind Alliance exercise; avoidance of hypoglycaemia was a target of all the other nine.48 Reducing hypoglycaemia burden also featured in the public consultation of priorities for revising the guidelines for the management of adults with type 1 diabetes for the UK’s NICE.44 People with diabetes were involved in creating the original curriculum for the pilot, and people with diabetes and carers were formally involved in the preparation of the revision. The trial has its own user group, members of which reviewed the protocol, advised on the potential burden of participation and informed the choice of primary endpoint and the name of the new intervention. The group continue to advise and actively assist recruitment, participating in the Trial Management Group (TMG).
Our primary outcome is the difference in rate of SH events (number of events over preceding year) between the two arms, measured using 12-month and 24-month anonymised recall forms and adjusted for baseline SH rate. Significantly lower event rates for HARPdoc as compared with BGAT at either 12 months postrandomisation, 24 months postrandomisation or both will be considered to indicate superiority of the HARPdoc treatment.
We will also compare between the two groups parameters to assess aspects of hypoglycaemia experience and other impacts of the intervention adjusted for baseline and other previous timepoints where appropriate at 12 and 24 months postrandomisation (table 3, refs 46 47 49–53).
As change in therapy modality such as new uptake of pumps and/or sensors (CGM) will impact on SH rate, we will describe the numbers of people making such changes in each group, namely: introduction of novel (to that participant) pump, CGM, automated insulin infusion adjustment technology, use of retrospective intermittently monitored ‘Flash’ glucose monitoring, islet or pancreas transplantation and psychiatric or psychological therapy external to the trial.
Outside the main study analyses, we also propose to compare between groups at 12 and 24 months, adjusting for baseline where appropriate:
Exposure to plasma glucose readings of: (1) under 3.9 mmol/L and (2) under 3 mmol/L as event rates and percent of all readings made per patient per week on home glucose monitoring records, including retrospective intermittently monitored ‘Flash’ CGM glucose readings at time of monitoring from 2 weeks (14 days) prior to data collection.
Total score on Hypoglycaemia Cues Questionnaire.54
Health economics analysis
An economic evaluation will examine the cost-effectiveness of HARPdoc compared with BGAT within a cost-per quality adjusted life year (cost–utility) framework,57 using trial data from all UK sites. The base-case economic evaluation will be carried out from and NHS/personal social services perspective. As part of a sensitivity analysis around base-case findings, a secondary ‘societal’ analysis will assess whether inclusion of employment-related costs linked to severe hypo events (specifically work time lost) and the costs of service contacts outside of the NHS (specifically psychological treatment services) impacts on base-case cost-effectiveness conclusions.58
Parallel implementation study
Under a separate protocol, researchers, participants and people who did not participate will be invited to contribute to an implementation study, which will aim formally to evaluate the way in which each trial intervention is being delivered in the context of the local services across study sites. This mixed methods study will collect a range of implementation outcome metrics (intervention acceptability, appropriateness and feasibility; intended adoption) from intervention providers and users; study the clinical and service user context in which the interventions are being delivered; and finally study the link between the quality of delivery of the trialled interventions and the expected improvements in the study endpoints.59 In carrying out a parallel evaluation of clinical and implementation endpoints and in correlating the two sets of endpoints as part of the overall trial, we are conducting what has recently been termed a ‘hybrid effectiveness-implementation type II’ study.60 The implementation study has a study protocol, coauthored with service users and reported separately in detail.61
The timeline for the study is shown in table 5. Potential participants will be invited to express interest in the study by their diabetes healthcare professional. Those expressing interest will receive the participant information sheet (online supplementary file 2) and an opportunity to discuss the study with a member of the research team. If they wish to proceed, they will sign a consent form and be allocated a unique study number. Initial screening will include recall of SH episodes over the previous 1 and 2 years and of hypoglycaemia awareness status (figure 1A). Participants will start prospective recording of SH, using study forms (figure 2). Baseline data collection may be contemporaneous with screening if the course is due in less than 1 month. Participants who have undergone significant change in therapy since screening and have had resolution of their hypoglycaemia issues will not be randomised and will be replaced. Follow-up sessions will be at 3, 6, 12, 18 and 24 months after randomisation and include 2-hour group revision sessions for HARPdoc participants in the first year.
Supplementary file 2:
The study is powered as a superiority study. We estimate that 96 participants will give us 90% power to detect a difference in our primary endpoints at 2.5% level of significance with a 20% attrition rate. To ensure adequate recruitment to each course, we may recruit to a maximum of 120.
The sample size calculation used the published data on the base rates and impact of the two interventions in this highly selected population. The mean rate of SH at the start and end of the pilot for HARPdoc, DAFNE-HART, was 19 per year falling to 0.5 per subject year at 12 months.41 For the present study, we considered also a more conservative estimate of HARPdoc success, namely two SH events per person per year. For BGAT, we used an outcome of 3.8 episodes per year, the mean achieved value of three published studies.27–29 We inflated the sample size to take account of within-group correlation and adjusted for therapist group, for which the intraclass correlation has been estimated as 0.02.63 It is envisaged that therapy groups will have 6–8 patients giving a design effect of 1+0.02 (8–1)=1.14. We further adjusted for multiple comparison with the use of Bonferroni correction in two endpoints (12 and 24 months) (corrected alpha=0.025%).
Assignment of interventions
Once a centre has recruited 8–16 eligible participants, their data will be checked for eligibility by the clinical trial manager and entered into the randomisation system, provided by the King’s Clinical Trials Unit, no more than a week before the course start date.
The randomisation system randomly sequences the order of the participants and enters them into the study stratifying by country and by technology use (use of pumps and/or CGM systems, not including use of intermittently monitored retrospective CGM (‘Flash’) glucose monitoring). Non-randomised participants will undertake the same procedures, but their data will not be included in the main trial analysis.
Should anyone become ineligible between screening and randomisation (eg, if they have changed their treatment modality and ceased to have problematic hypoglycaemia), or they wish to withdraw, they can be replaced by a newly recruited person. Once a person is randomised to the study, they remain in the study unless he or she chooses to withdraw or they are withdrawn.
The clinical trial manager will be informed of the randomisation outcome and relays the information to the centre, usually all by e mail. Local educators inform participants which group they will attend by telephone, email or in person on the morning of the first day, where practical. Where possible, HARPdoc and BGAT courses will be run simultaneously.
Participants researchers and participants’ usual care providers cannot be blinded to course allocation once the randomisation is complete. The trial statisticians remain blinded to group allocation throughout.
Apart from a blood test for glycated haemoglobin, taken at baseline, 12 and 24 months and sent to Viapath at King’s College Hospital London for central measurement by High Pressure Liquid Chromatography (HPLC) methods, all outcome data will be collected by questionnaires. Validated questionnaires are listed in table 3 and above. The questionnaires for collecting data on hypoglycaemia experience are purpose-built for the study, based on tools used in earlier research, particularly the UK Hypoglycaemia Study Group data forms.64 Participants will complete two versions of forms detailing their recall of SH. One (Figure 1A) is open and can be discussed with the researchers to be confident of shared definitions of SH. The other (Figure 1B), which will be used for the primary outcome, is anonymised, mailed to a non-clinical study data manager for direct entry into the study electronic database, without clinical review. This is because of evidence of under-reporting of SH since the introduction of European guidelines mandating loss of driving privileges for people reporting more than one SH in a year.65 A further questionnaire is included for the participant to give to a close relative or friend, for an independent assessment of their SH experience (figure 1C). Data on SH involving unscheduled care will be collected from primary care services.
Forms for anonymously recording SH immediately (form A) and monthly (form B) will be mailed out by local centres, and their research teams remind participants to return the monthly forms (figure 2). All anonymised forms will remind participants that their diabetes team will not see these data and to contact their educators if they want advice.
The open 12-month and 24-month recall form, Gold, DAFNE and Clarke scores for hypoglycaemia awareness and all the other questionnaires will be sent to participants in a booklet, with the anonymised and the relatives’ SH recall forms in the week before courses and before 12-month and 24-month follow-up.
Should a participant decide to withdraw, efforts will be made to report the reason for withdrawal. If the participant has been randomised, efforts will be made to continue to obtain follow-up data. Participants will remain under services that routinely collect the data of our main endpoints (SH rate, HbA1c and Gold score). We will collect case record data ±1.5 months of due dates via the participants’ usual diabetes care provider, subject to participant permission.
Data will be collected onto paper clinical record forms (CRFs), then uploaded by research administrative staff into a study-specific electronic database constructed and managed for the trial by the King’s College London (KCL) Clinical Trials Unit using the participant’s unique study identifier. The clinical trial manager and the study data manager will review the electronic data base and will visit each centre to check the data entry against the paper CRFs. Patient data will be managed in line with the General Data Protection Act 2018. The trial will be monitored by the King’s Clinical Trial Office. The chief investigator will act as custodian for the trial data.
The main statistical analyses will be carried out by the trial statistician who will be blind to the group randomisation until the main analyses are complete. The analyses outlined in this strategy will be primarily based on intention to treat. A per-protocol analysis will also be conducted in which the primary outcome will also be compared between groups, removing data of participants who:
1. Do not complete their intervention as defined above.
2. Delay undertaking their intervention by more than 2 months after randomisation.
3. Are later found to have an exclusion criterion that was missed, including those who become pregnant.
4. Undertake islet or pancreas transplant.
Data from participants who become pregnant or undergo transplantation will be retained until the event. The numbers of participants who escalate their therapy to include new technology will be documented for each group.
The first stage of analyses will be a descriptive model of the data to assess completeness of data. Participant-level baseline variables will be described both overall and by randomised groups, country and centre. Patterns of missing data will be described.
The primary outcome will be analysed using Poisson or negative binominal linear mixed models, depending on the dispersion of the data, to model the difference in SH rate (number of SH events over the preceding year) at 1 and 2 years’ postrandomisation. The Poisson or negative binomial linear mixed models will be adjusted for baseline SH rate (events in the year preceding baseline) and stratification factors (country and using technology). The model will use a random intercept for each therapy group to account for clustering. A three-level hierarchical model will be employed with all time points included as repeated measures in the model (12 and 24 months) to improve power and take into account clustering of the observation at patient and group therapy level.
These models use maximum likelihood estimation and thus allow for missing outcome data under the missing at random (MAR) assumption. Associations between postrandomisation variables and missingness will be dealt with by multiple imputation, again under the MAR assumption. Departures from this assumption will be assessed with a sensitivity analysis.
Secondary outcomes will be assessed with a similar methodology for the primary outcomes, using generalised linear mixed models depending on the type of outcome (normal, binary and count). The questionnaires to be used have validated methods of scoring, and the scores will be analysed as described.
A Data Monitoring Committee (DMC), Trial Steering Committee (TSC) and TMG comprising all PIs, the statisticians and chairman of the trial’s user group have been established to oversee the study. The DMC and TSC are described below. The DMC will review SH rates and can stop the trial if one arm is dangerously underperforming. The Chief Investigator (CI) and/or clinical trial manager will visit each site at setup and at least annually during the study. The trial will be monitored by the King’s Health Partners Clinical Trials Office to ensure compliance with Good Clinical Practice.
Adverse events will be recorded in the medical records. Data on diabetic ketoacidosis, falls and fractures and starting or stopping therapy (medical or psychotherapeutic) for psychiatric events will be recorded in the CRFs from time of consent to final data collection. SH will be collected throughout the trial using trial documentation (12 and 24 month recall and forms A and B) and not reported as an adverse event.
At worst, participants will remain at their baseline SH risk. SH rates will be monitored by the DMC. For individual participants, if their SH persists unchanged, other strategies will be explored. As participants should have already experienced optimal conventional care, these options are limited but may include offers of technology for glucose sensing or insulin delivery (CGM and pump) that were not previously available to that participant and referral for islet or pancreas transplantation. Requirement for other therapies, such as psychological interventions, will be assessed on an individual basis. It should however be noted that desire to engage with a new technology or treatment that has previously not been successful or acceptable to a participant may well be a positive result of engaging in a study course and previous exposure to such technologies will be collected at baseline.
We will report the results of the trial to the participants through written and verbal reports, with further dissemination at national/international conferences and in peer-reviewed scientific journals. We will also report to people with diabetes and their carers through publications (electronic and/or paper) of the Juvenile Diabetes Research Foundation and the South London National Institute of Health Research Collaboration for Leadership in Applied Health Research and Care South London and by presentations to patient groups. There has been interest from the US healthcare provider, Kaiser Permanente, with which we hope to work on scaling up the successful intervention in the USA.
The authors would like to thank the patients who are taking part in this study. The research is sponsored by King’s College Hospital National Health Service (NHS) Foundation Trust and King’s College London. The clinical sites taking part are Guy’s and St Thomas’ NHS Foundation Trust, the Joslin Diabetes Center, Boston, Massachusetts, USA, King’s College Hospital NHS Foundation Trust and the Royal Bournemouth General Hospital, Bournemouth, Dorset, UK, with Patient Identification Sites at St Mary’s Hospital, Paddington (Professor Nick Oliver), East Kent Hospitals University NHS Foundation Trust (Dr Stonny Joseph), Royal Sussex County Hospital, Brighton and Sussex Universities Hospitals (Dr Ali Chakera), Royal Free London NHS Foundation Trust (Dr Miranda Rosenthal) and St George’s Hospitals NHS Foundation Trust (Drs Nicola Neary and Arshia Panaloo). The authors would also like to thank Caroline Murphy and the KCL Clinical Trial Unit for providing the randomisation procedures and the electronic data base; Marilyn Ritholz for additional psychological support; Sean Haywood and Karolina Burakowska for central trial administration; diabetes educators Monet Bland, Carly Devin, Victoria Francis, Val Gordon, Emma Jenkins, Lois Maurer, Sarah Newall, Nicole Patience, Jacqueline Ryder, Jill Rimmel, Helen Rogers and Melanie Weiss, and researchers Astrid Atakov-Castillo, Sharon Caunt, Tanith Changuion, Linda Greaves, Gail Hann, Sue Hudson, Chloe Nisbet, Marius Racz, Elsa Redfern and Navone Thompson, and our patient representative group Mike Kendall (chair), Richard Lane, OBE, Lis Warren, Mel Stephenson, Vicky Ruzala and Arthur Durrant.
Contributors SA wrote the first draft of the manuscript and designed this study, with input from all the listed authors. NDZ, with SA, HR, PC and SH, designed the DAFNE-HART/HARPdoc (Dose Adjustment for Normal Eating-Hypoglycaemia Awareness Restoration Training) programme and training curriculum for HARPdoc educators, with support from the UK DAFNE collaborative and patient group; ELS led this group on the update for the trial; LG-F wrote the original Blood Glucose Awareness Training (BGAT) programme and led the revision, with SA, MS, PJ and MK and support from the BGAT educators. MS and PC designed the continuous glucose monitoring substudy. KG, IB and LP wrote the statistical analysis plan and power calculations and commented on the final form of the protocol and choice of end points. AH designed the health economic study; MK supported by the Patient and Public Involvement (PPI) group and reviewed the protocol and all the patient-facing papers; DK, ET, SH and AB reviewed the protocol, supported the training of the educators and set up the study sites; MQ runs the database and administers the trial. NS designed and leads the implementation science protocol. All authors have read and contributed significantly to the manuscript and approved its final form.
Funding This project is funded by the Juvenile Diabetes Research Foundation Project Grant no 4- SRA-2017-266-M-N, with additional support from the UK’s National Institute of Health Research (NIHR) through the South London Collaboration for Leadership in Applied Health Research and Care South London (CLAHRC) at King’s College Hospital NHS Foundation Trust, London, UK. NS, AH and IB are also members of King’s Improvement Science, part of the NIHR CLAHRC South London based at King’s College London and funded by King’s Health Partners (Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospital NHS Foundation Trust, King’s College London and South London and Maudsley NHS Foundation Trust), Guy’s and St Thomas’ Charity, the Maudsley Charity and the Health Foundation. The study is sponsored jointly by King’s College London (Professor Rezavi, email@example.com) and King’s College Hospital NHS Foundation Trust, (Research & Innovation Office, firstname.lastname@example.org).
Disclaimer The funders had no role in the design, conduct or analysis of this study. The views expressed are those of the authors and not necessarily those of the Juvenile Diabetes Research Foundation International (JDRF), the NHS, the NIHR or the Department of Health and Social Care.
Competing interests SA is a member of the International Hypoglycaemia Study Group and has served on advisory panels for Roche, Medtronic and NovoNordisk. AB has received honoraria from Astra Zeneca and Sanofi for speaking at educational events and sponsorship from Lilly and Janssen to attend conferences. SH has served as a consultant or speaker from Lilly, Novo Nordisk, Takeda, Boeringher Ingelheim, Mannkind, Sanofi, Zealand Pharma and UN-EEG. NS is the Director of London Safety and Training Solutions Ltd, which provides quality and safety training and advisory services on a consultancy basis to healthcare organisation globally.
Ethics approval The protocol for the study has been approved by the London Dulwich Research Ethics Committee (IRAS number 216381), and the Health Research Authority with additional approvals for the US centre obtained from the Institutional Review Board of the Joslin Diabetes Center.
Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.
Author note The trial steering committee members are: Professor James Shaw, Newcastle University (chair), Richard Holt (chair) and Irene Stratton, Gloucester Hospitals NHS Foundation Trust; the independent data monitoring and ethics committee members are Amanda Adler (Addenbrookes Hospital Cambridge), Steve Sharp (MRC Epidemiology Unit, University of Cambridge) and Mark Evans (University of Cambridge).
Patient consent for publication Not required.